贾斯珀治疗公司因制造和试验的误导性说法而面临诉讼,在2025年7月出现关键药物问题后,导致股价暴跌55%. Jasper Therapeutics faces a lawsuit over misleading claims about manufacturing and trials, causing a 55% stock plunge after critical drug issues surfaced in July 2025.

贾斯珀治疗公司(JSPR)因据称在2023年11月30日至2025年7月3日期间就其第三方制造控制和临床试验完整性所作的虚假或误导性陈述而面临证券集团诉讼。 Jasper Therapeutics, Inc. (JSPR) is facing a securities class action lawsuit over alleged false or misleading statements made between November 30, 2023, and July 3, 2025, regarding its third-party manufacturing controls and clinical trial integrity. 该诉讼声称,该公司未能确保遵守CGMP条例,有可能损害试验数据,并损害其药物briquilimab的可靠性,导致2025年7月披露后库存下降55.1%,暴露出关键产品批量问题,并阻碍了关键领域的发展。 The lawsuit claims the company failed to ensure compliance with cGMP regulations, risking compromised trial data and undermining the reliability of its drug briquilimab, leading to a 55.1% stock drop after a July 2025 disclosure revealed critical product lot issues and halted development in key areas. 2025年11月18日是提出赔偿要求的最后期限,在此类别期间购买JSPR股票的投资者可能有资格加入该案。 Investors who bought JSPR stock during the class period may be eligible to join the case, with a November 18, 2025, deadline to file a claim. 几家律师事务所正在以应急收费方式处理此案,投资者无需预付费用。 The case is being handled by several law firms on a contingency fee basis, with no upfront cost to investors.